Canadian Natural Resources Ltd. (CNQ) Stock Price Today
Aura AI Summary
Key Stats
- $101.17BMarket Cap
- 4,046,754Volume
- EnergySector
- $56.1252W High
- $30.5952W Low
- 73 DaysTypical Hold Time
- $109.66BEnterprise Value
- 3.6%Div Yield
- -Trading Activity
Track Canadian Natural Resources Ltd. (CNQ) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Canadian Natural Resources Ltd. has traded between a low of $30.59 and a high of $56.12, highlighting its annual price range. Buy and sell Canadian Natural Resources Ltd. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Most Recent News
Vietnam plastics market to reach 20.47 million tons by 2032, driven by construction and packaging growth.
The Vietnam plastics market is projected to grow at a CAGR of 8.05% from 2027 to 2032, increasing from 13.9 million tons in 2027 to 20.47 million tons by 2032. Growth is fueled by expanding construction activities, rising demand for food-grade and e-...

58% of Latin American mining execs favor democratic nation investment despite infrastructure gaps
A survey of Latin American mining executives reveals 58% support prioritizing investment from democratic countries for critical minerals, even at some economic cost. However, only 21% believe their countries have adequate infrastructure, and just one...

FDA approves Cosentyx as first anti-IL-17 biologic for polymyalgia rheumatica treatment
The FDA has approved Novartis' Cosentyx (secukinumab) 150 mg for treating adults with polymyalgia rheumatica (PMR) who do not respond well to or cannot tolerate corticosteroids. This marks the first anti-IL-17 biologic approved for PMR, offering a ne...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.